BenzingaDoubao · 实盘不做把握 8/10不做原因:风险收益比不佳
北京时间·🕒 发布 02:07:08·⟳ 抓取 02:07:13 +5s·⚡ 决策 10-20 02:08:52 +1m39s·7.8 天前
吉利德口服α4β7抑制剂emvistegrast（GS-1427）II期SWIFT溃疡性结肠炎诱导期数据阳性，股价盘中不涨反跌
数据本身真实且阳性，但属于超大盘公司（约1921亿美元市值）的II期临床软催化：无收入、无交易金额、距III期/申报/商业化仍有数年，单一早期资产增量相对市值可忽略；盘中股价下跌0.8%直接证实市场未给予正重定价，做多无edge。竞品层面也不构成可做空的实质利空。
📄 原文Benzinga↗ 原文
Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success
Gilead Sciences Inc. (NASDAQ:GILD) on Monday announced 12-week induction data from its Phase 2 SWIFT trial evaluating e…
不做 Gilead Sciences（GILD.US）
超大盘（约1921亿美元市值）自有资产的II期阳性软催化，距III期与商业化数年、无收入/订单增量，相对市值弹性可忽略；盘中利好股价反跌0.8%、无放量重定价，做多无正期望；对竞品亦不构成可做空利空，故不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
吉利德自有口服α4β7抑制剂II期溃疡性结肠炎数据阳性（应答66% vs 37%），但对1921亿美元市值公司只是早期管线期权、无近期业绩增量，股价盘中反跌0.8%，不具可交易edge，回避。
🔎 新鲜度:最早出现 2026-10-19 · 扩散 low · price-in 风险 low ↗
消息传播链
- 盘中即时报道吉利德在UEG Week 2026公布emvistegrast II期SWIFT 12周诱导阳性数据；发表时GILD报155.02美元、跌0.75%市场反应:报道时及研判时（约154.94美元）均下跌约0.8%，无放量同向重定价（量比约1.3）
关键理由
- II期阳性降低了该资产的技术风险，但维持期数据、III期与上市仍需数年，2026年无任何收入贡献
- GILD约1921亿美元市值，单一II期资产相对市值弹性极小，盘中-0.8%说明资金不认可为短线催化
主要风险
- 维持期数据或后续III期失败将证伪当前阳性，且事件本身已被市场视为非重大
- 若解读为相对竞品差异化显著，短期情绪可能小幅修复，但向上空间不足以补偿追高风险
反向证据
- 做多前查反向 · 来源 web · 影响 none
未发现安全性恶化或竞品冲击等额外利空；但正向反证（收入增量/外部背书）同样缺失，II期数据属公司内部管线进展
检索:Gilead GS-1427 emvistegrast safety setback maintenance failure competitive Entyvio risk 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认回避：不依赖先例即可判定无正期望
方向:未构造历史先例面板：本事件为超大盘公司早期II期软催化，方向虽阳性但无短期基本面增量，且盘中实时价格已给出无反应的直接证据，先例统计不会改变materiality结论
涨幅量级:不足以校准任何止盈幅度，故不给出ENTER
形态:盘中利好而股价下跌本身即为典型的'软催化无人买单'信号
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`gilead emvistegrast gs-1427 phase 2 swift ulcerative colitis 12-week induction data | gilead sciences α4β7 integrin inhibitor ueg week 2026 trial results`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 655 ms
{ - web_search 成功 doubao_search · 1,577 ms
豆包搜索结果（原始查询:Gilead emvistegrast GS-1427 Phase 2 SWIFT ulcerative colitis license partner origin；API SearchType:web）
原文全文
展开原文 · 2,230 字
Gilead Sciences Inc. (NASDAQ:GILD) on Monday announced 12-week induction data from its Phase 2 SWIFT trial evaluating emvistegrast, an investigational once-daily oral treatment for adults with moderately to severely active ulcerative colitis.
The biopharmaceutical company revealed the late-breaking findings on Monday at the United European Gastroenterology Week 2026.
The trial evaluated whether the selective oral α4β7 integrin inhibitor, also known as GS-1427, could address the substantial unmet need in inflammatory bowel disease.
Key Efficacy Findings
The 200 mg dose of emvistegrast met the primary efficacy goal. At Week 12, 66% (39 of 59) of patients receiving the 200 mg dose achieved a clinical response based on the modified Mayo score, compared to 37% (22 of 60) in the placebo cohort.
The candidate also demonstrated statistically significant gains across several secondary endpoints. Approximately 31% (18 of 59) of patients on emvistegrast reached clinical remission, compared with 8% (5 of 60) on placebo.
Furthermore, 39% of participants receiving the 200 mg dose achieved endoscopic improvement versus 12% on placebo. Histological endoscopic mucosal improvement occurred in 25% of emvistegrast patients compared to 10% on placebo, while mucosal healing reached 24% versus 10%.
Tolerability And Next Steps
The patient population included individuals with varied treatment backgrounds. While 78% were naive to advanced therapies or had not failed prior advanced treatments, 22% had previously failed one or two advanced regimens.
Emvistegrast demonstrated a generally well-tolerated safety profile during the induction phase. Adverse events occurred in 36% (64 of 178) of emvistegrast participants and 37% (22 of 60) of placebo recipients, with most cases remaining Grade 2 or lower.
Gilead continues the SWIFT study as planned, with upcoming analyses evaluating long-term maintenance outcomes.
GILD Price Action: Gilead Sciences shares were down 0.75% at $155.02 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
The biopharmaceutical company revealed the late-breaking findings on Monday at the United European Gastroenterology Week 2026.
The trial evaluated whether the selective oral α4β7 integrin inhibitor, also known as GS-1427, could address the substantial unmet need in inflammatory bowel disease.
Key Efficacy Findings
The 200 mg dose of emvistegrast met the primary efficacy goal. At Week 12, 66% (39 of 59) of patients receiving the 200 mg dose achieved a clinical response based on the modified Mayo score, compared to 37% (22 of 60) in the placebo cohort.
The candidate also demonstrated statistically significant gains across several secondary endpoints. Approximately 31% (18 of 59) of patients on emvistegrast reached clinical remission, compared with 8% (5 of 60) on placebo.
Furthermore, 39% of participants receiving the 200 mg dose achieved endoscopic improvement versus 12% on placebo. Histological endoscopic mucosal improvement occurred in 25% of emvistegrast patients compared to 10% on placebo, while mucosal healing reached 24% versus 10%.
Tolerability And Next Steps
The patient population included individuals with varied treatment backgrounds. While 78% were naive to advanced therapies or had not failed prior advanced treatments, 22% had previously failed one or two advanced regimens.
Emvistegrast demonstrated a generally well-tolerated safety profile during the induction phase. Adverse events occurred in 36% (64 of 178) of emvistegrast participants and 37% (22 of 60) of placebo recipients, with most cases remaining Grade 2 or lower.
Gilead continues the SWIFT study as planned, with upcoming analyses evaluating long-term maintenance outcomes.
GILD Price Action: Gilead Sciences shares were down 0.75% at $155.02 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
28ee9e5a2b· 2026-10-20 02:08 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前